YORVIPATH in breast milk study
Part of Hormones & metabolism clinical trials.
This study measures how much of the medicine YORVIPATH (palopegteriparatide) gets into breast milk. It helps mothers who need this medicine and want to breastfeed understand if it is safe for their baby.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman who is breastfeeding (or planning to breastfeed) and at least 18 years old.
- You have been taking YORVIPATH as part of your regular medical care for at least 14 days before the study starts.
- Your baby’s main food is breast milk. For the 14 days before the study, you can give only one small bottle (up to 8 ounces) of formula per day.
- Your dose of YORVIPATH has not changed in the last 14 days.
- If you are invited from another source, you must also join a Pregnancy Registry before joining this study.
- You must agree to sign a consent form (in writing or electronically).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tracks the health of mothers and babies who were exposed to YORVIPATH (a medicine for hypoparathyroidism) around the time of pregnancy or while breastfeeding. It aims to understand if the medicine affects pregnancy outcomes or infant health.
This trial is for adults with hypoparathyroidism who are already taking a drug called palopegteriparatide (TransCon PTH) at a certain dose. It tests whether higher doses of this drug can better control calcium levels and reduce the need for other supplements.
This study tests a new medicine called palopegteriparatide for teenagers with long-term hypoparathyroidism (low parathyroid hormone). The medicine is given as a daily injection and aims to help control calcium levels.
This trial tests an investigational drug called XH02 for people with hypoparathyroidism (low parathyroid hormone) that is not well controlled with standard calcium and vitamin D treatments. The goal is to see if XH02 is safe and effective at managing symptoms.
This trial tests an experimental drug called Canvuparatide against a placebo to see if it can help adults with a condition called hypoparathyroidism, where the body doesn't make enough parathyroid hormone. The goal is to improve calcium levels and reduce the need for high-dose calcium and vitamin D supplements.
This trial tests a new medicine called EXT608 for adults with hypoparathyroidism. It aims to see if this medicine can help manage calcium levels better than current treatments.
Hear when a new Hypoparathyroidism trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.